LEXINGTON, Mass., July 13, 2026
Voyager Therapeutics presented new six-month good laboratory practice (GLP) toxicology data demonstrating that its investigational Alzheimer’s disease gene therapy VY1706 was well tolerated and achieved sustained reductions of tau protein by up to 75% in key brain regions following a single intravenous dose. The findings were presented as a late-breaking Developing Topics poster at the Alzheimer’s Association International Conference (AAIC) 2026 in London. The positive results build upon the company’s recent FDA Investigational New Drug (IND) clearance and support initiation of a first-in-human clinical trial in adults with early Alzheimer’s disease during the second half of 2026..
Single-Dose Gene Therapy Demonstrates Durable Tau Reduction
The six-month GLP toxicology study conducted in non-human primates showed that a single intravenous administration of VY1706 achieved broad, dose-dependent delivery throughout the central nervous system while maintaining durable reductions in both MAPT mRNA and tau protein. Researchers observed up to 75% lowering of tau across Alzheimer’s disease-relevant brain regions over the six-month evaluation period. The therapy employs a vectorized siRNA designed to simultaneously reduce intracellular and extracellular tau, one of the primary pathological proteins associated with neurodegeneration and cognitive decline in Alzheimer’s disease.
Preclinical Data Confirm Favorable Safety and Brain Delivery
The study demonstrated a favorable safety profile across all tested dose levels, with no adverse clinical pathology or histopathological findings observed in the central nervous system, dorsal root ganglia, liver, or other peripheral organs. Voyager also reported that its proprietary TRACER™ AAV capsid successfully crossed the blood-brain barrier through interaction with the ALPL endothelial receptor, enabling efficient brain delivery following intravenous administration. According to the company, this receptor-mediated transport mechanism may support translation across multiple species and potentially simplify systemic administration compared with other gene therapy approaches targeting neurological disorders.
Advertisement
Voyager Advances First FDA-Cleared Tau Gene Therapy for Alzheimer’s Disease
Following FDA IND clearance received in June 2026, Voyager plans to begin dosing adults with early Alzheimer’s disease later this year, making VY1706 the first tau-targeted gene therapy cleared by the agency for clinical evaluation. The investigational therapy is designed as a one-time intravenous treatment that combines a potent tau-targeting siRNA with the company’s proprietary brain-penetrating AAV delivery platform. Supported by encouraging six-month durability, sustained tau reduction, and favorable tolerability findings, Voyager believes VY1706 has the potential to modify disease progression by directly targeting one of the central biological drivers of Alzheimer’s disease while expanding the application of systemic gene therapy for neurodegenerative disorders.
Source: Voyager Therapeutics, press release
